GlassScriptPhysician profile
Robert S Shires
NPI 1780643163
$2,804.64
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,131 · 2020: $673.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $442.82 | 2019-2020 | |
| Novo Nordisk INC | $407.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $257.92 | 2019-2020 | |
| Lilly USA, LLC | $221.42 | 2019-2020 | |
| Pfizer INC. | $219.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $200.31 | 2019-2020 | |
| Glaxosmithkline, LLC. | $167.25 | 2019-2020 | |
| Amgen INC. | $162.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.24 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $60.86 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.88 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $34.00 | 2020 | |
| Merck Sharp & Dohme LLC | $29.66 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $19.32 | 2020 | |
| Astellas Pharma US INC | $17.46 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.82 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.16 | 2019 | |
| Abbvie INC. | $11.63 | 2020 | |
| Shire North American Group INC | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.